Works by Ryu, Min-Hee
Results: 139
Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
- Published in:
- Journal of Surgical Oncology, 2008, v. 98, n. 1, p. 27, doi. 10.1002/jso.21065
- By:
- Publication type:
- Article
Heterogeneity of claudin 18.2 expression in metastatic gastric cancer.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-68411-w
- By:
- Publication type:
- Article
Methylation of specific CpG sites in the promoter region could significantly down-regulate p16.
- Published in:
- International Journal of Cancer, 2000, v. 87, n. 2, p. 236, doi. 10.1002/1097-0215(20000715)87:2<236::AID-IJC14>3.0.CO;2-M
- By:
- Publication type:
- Article
Human epidermal growth factor receptor 2 testing in gastric cancer: Recommendations of an Asia- Pacific Task Force.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2014, v. 10, n. 4, p. 297, doi. 10.1111/ajco.12263
- By:
- Publication type:
- Article
Serum CA 19-9 as a prognostic factor in patients with metastatic gastric cancer.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2013, v. 9, n. 4, p. 324, doi. 10.1111/ajco.12019
- By:
- Publication type:
- Article
Alteration of Signal-Transducing Molecules and Phenotypical Characteristics in Peripheral Blood Lymphocytes from Gastric Carcinoma Patients.
- Published in:
- Pathobiology, 1999, v. 67, n. 3, p. 123, doi. 10.1159/000028061
- By:
- Publication type:
- Article
A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours.
- Published in:
- British Journal of Cancer, 2023, v. 129, n. 2, p. 275, doi. 10.1038/s41416-023-02269-z
- By:
- Publication type:
- Article
Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach.
- Published in:
- British Journal of Cancer, 2017, v. 117, n. 1, p. 25, doi. 10.1038/bjc.2017.144
- By:
- Publication type:
- Article
Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE).
- Published in:
- Cancer Medicine, 2023, v. 12, n. 7, p. 7784, doi. 10.1002/cam4.5536
- By:
- Publication type:
- Article
Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 3, p. 2572, doi. 10.1002/cam4.5123
- By:
- Publication type:
- Article
Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 3, p. 1034, doi. 10.1002/cam4.1994
- By:
- Publication type:
- Article
Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1.
- Published in:
- Gastroenterology Research & Practice, 2015, p. 1, doi. 10.1155/2016/6857625
- By:
- Publication type:
- Article
Over-the-wire versus through-the-scope stents for the palliation of malignant gastric outlet obstruction: A retrospective comparison study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Gastroduodenal stent placement versus surgical gastrojejunostomy for the palliation of gastric outlet obstructions in patients with unresectable gastric cancer: a propensity score-matched analysis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity.
- Published in:
- Oncology, 2012, v. 82, n. 5, p. 290, doi. 10.1159/000337989
- By:
- Publication type:
- Article
Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer.
- Published in:
- Oncology, 2012, v. 82, n. 2, p. 83, doi. 10.1159/000335959
- By:
- Publication type:
- Article
Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma.
- Published in:
- Oncology, 2012, v. 82, n. 2, p. 119, doi. 10.1159/000336082
- By:
- Publication type:
- Article
Adjuvant Chemotherapy for Small Bowel Adenocarcinoma after Curative Surgery.
- Published in:
- Oncology, 2011, v. 80, n. 3/4, p. 208, doi. 10.1159/000328506
- By:
- Publication type:
- Article
PDGFRα Gene Mutation and Protein Expression in Gastrointestinal Stromal Tumors.
- Published in:
- Oncology, 2008, v. 74, n. 1/2, p. 88, doi. 10.1159/000139136
- By:
- Publication type:
- Article
FDA regulatory considerations for oncology drug development.
- Published in:
- Pharmacology Research & Perspectives, 2024, v. 12, n. 4, p. 1, doi. 10.1002/prp2.1254
- By:
- Publication type:
- Article
Recent Advances in Chemotherapy for Advanced Gastric Cancer.
- Published in:
- Asia Pacific Journal of Oncology & Hematology, 2010, v. 2, n. 1, p. 67
- By:
- Publication type:
- Article
Hand-Foot Syndrome in Patients Treated with Capecitabine-Containing Combination Chemotherapy.
- Published in:
- Journal of Clinical Pharmacology, 2004, v. 44, n. 10, p. 1166, doi. 10.1177/0091270004268321
- By:
- Publication type:
- Article
Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 2, p. 1, doi. 10.1111/cts.13736
- By:
- Publication type:
- Article
Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression.
- Published in:
- Gastric Cancer, 2025, v. 28, n. 1, p. 74, doi. 10.1007/s10120-024-01566-7
- By:
- Publication type:
- Article
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
- Published in:
- Gastric Cancer, 2024, v. 27, n. 6, p. 1287, doi. 10.1007/s10120-024-01535-0
- By:
- Publication type:
- Article
SMARCA4-deficient undifferentiated gastric carcinoma: a case series and literature review.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 5, p. 1147, doi. 10.1007/s10120-024-01510-9
- By:
- Publication type:
- Article
Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 4, p. 840, doi. 10.1007/s10120-024-01509-2
- By:
- Publication type:
- Article
Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 4, p. 819, doi. 10.1007/s10120-024-01500-x
- By:
- Publication type:
- Article
Letter to the editor: 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 4, p. 884, doi. 10.1007/s10120-024-01496-4
- By:
- Publication type:
- Article
Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 4, p. 811, doi. 10.1007/s10120-024-01483-9
- By:
- Publication type:
- Article
Adjuvant treatment for locally advanced gastric cancer: an Asian perspective.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 3, p. 439, doi. 10.1007/s10120-024-01484-8
- By:
- Publication type:
- Article
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 2, p. 375, doi. 10.1007/s10120-023-01455-5
- By:
- Publication type:
- Article
DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial
- Published in:
- Gastric Cancer, 2024, v. 27, n. 1, p. 110, doi. 10.1007/s10120-023-01434-w
- By:
- Publication type:
- Article
Clinical outcomes of Epstein–Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 1, p. 146, doi. 10.1007/s10120-023-01445-7
- By:
- Publication type:
- Article
Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions.
- Published in:
- Gastric Cancer, 2023, v. 26, n. 4, p. 604, doi. 10.1007/s10120-023-01377-2
- By:
- Publication type:
- Article
Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 6, p. 1039, doi. 10.1007/s10120-022-01325-6
- By:
- Publication type:
- Article
Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 4, p. 794, doi. 10.1007/s10120-022-01298-6
- By:
- Publication type:
- Article
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 609, doi. 10.1007/s10120-021-01276-4
- By:
- Publication type:
- Article
Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 170, doi. 10.1007/s10120-021-01243-z
- By:
- Publication type:
- Article
Insertion–deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 226, doi. 10.1007/s10120-021-01233-1
- By:
- Publication type:
- Article
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 207, doi. 10.1007/s10120-021-01230-4
- By:
- Publication type:
- Article
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 197, doi. 10.1007/s10120-021-01227-z
- By:
- Publication type:
- Article
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.
- Published in:
- Gastric Cancer, 2021, v. 24, n. 4, p. 946, doi. 10.1007/s10120-021-01173-w
- By:
- Publication type:
- Article
Expression of the immune checkpoint molecule V-set immunoglobulin domain-containing 4 is associated with poor prognosis in patients with advanced gastric cancer.
- Published in:
- Gastric Cancer, 2021, v. 24, n. 2, p. 327, doi. 10.1007/s10120-020-01120-1
- By:
- Publication type:
- Article
Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial).
- Published in:
- Gastric Cancer, 2021, v. 24, n. 1, p. 156, doi. 10.1007/s10120-020-01101-4
- By:
- Publication type:
- Article
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
- Published in:
- Gastric Cancer, 2020, v. 23, n. 3, p. 510, doi. 10.1007/s10120-019-01034-7
- By:
- Publication type:
- Article